A multi-biomarker follow-up study of patients with multiple sclerosis.
This study aimed to examine the levels of the macrophage marker sCD163 and other biomarkers at the time of diagnosis of patients with either clinically isolated syndrome (CIS) or relapsing-remitting multiple sclerosis (RRMS), and assess relation to clinical indicators of prognosis, disease activity (DA), and changes in the levels of these biomarkers at follow-up.



The clinical status and MRI were reevaluated in 56 patients more than 1 year after diagnosis with a median follow-up time of 2 years. Levels of biomarkers in serum and cerebrospinal fluid (CSF) samples were evaluated by enzyme-linked immunosorbent assays.



There was no significant difference in time to DA between patients with CIS and RRMS. A high sCD163 ratio (>0.07) was significantly (P= 0.04) associated with time to DA in the untreated patient group. In 21 patients reevaluated with serum and CSF samples, the sCD163 ratio levels decreased from 0.068 to 0.054 (P= 0.026) in the CIS/RRMS-treated group. The CSF CXCL13, CXCL13 ratio, CSF neurofilament light polypeptide and osteopontin levels also decreased significantly in the CIS/RRMS-treated group.



The levels of all biomarkers changed concurrently with MS treatment. The sCD163 ratio was identified as a potential novel marker for time to DA.
Department of Neurology Aarhus University Hospital Nørrebrogade 44 DK-8000 Aarhus C Denmark; Department of Biomedicine Aarhus University Bartholin Building, Wilhelm Meyers Allé 4 DK-8000 Aarhus C Denmark.
Morten
M
Stilund
Department of Biomedicine Aarhus University Bartholin Building, Wilhelm Meyers Allé 4 DK-8000 Aarhus C Denmark.
Mikkel Carstensen
MC
Gjelstrup
Department of Biomedicine Aarhus University Bartholin Building, Wilhelm Meyers Allé 4 DK-8000 Aarhus C Denmark.
Tove
T
Christensen
Department of Clinical Biochemistry Aarhus University Hospital Nørrebrogade 44 DK-8000 Aarhus C Denmark.
Holger Jon
HJ
Møller
Department of Neurology Aarhus University Hospital Nørrebrogade 44 DK-8000 Aarhus C Denmark.
Thor
T
Petersen
Biomarker; cerebrospinal fluid; disease activity; multiple sclerosis; soluble CD163
Scand J Immunol. 2014 Dec;80(6):417-23
25346048
Mult Scler. 2007 Apr;13(3):336-42
17439902
J Neurol. 2013 Jun;260(6):1583-93
23377434
J Neurol Neurosurg Psychiatry. 2011 Jan;82(1):78-82
20802029
PLoS One. 2014 Jun 02;9(6):e98588
24886843
Neurology. 2009 Dec 8;73(23):2003-10
19996075
Ann Neurol. 2000 Jun;47(6):707-17
10852536
J Neuroimmunol. 2002 Jan;122(1-2):132-9
11777552
Mult Scler. 2011 Feb;17(2):164-72
20965960
Mult Scler. 2012 Apr;18(4):394-5
22473501
J Gastroenterol Hepatol. 2015 Aug;30(8):1293-300
25772748
Mult Scler. 2012 May;18(5):552-6
22492131
J Neurol. 2008 Jul;255(7):1023-31
18535872
Brain Behav. 2016 Jul 11;6(9):e00509
27688939
Nat Rev Immunol. 2012 Jan 06;12(2):125-35
22222875
Lancet. 2008 Oct 25;372(9648):1502-17
18970977
Mult Scler. 2011 Mar;17(3):335-43
21135023
Neurology. 2014 Jul 15;83(3):278-86
24871874
J Leukoc Biol. 2000 Jan;67(1):97-103
10648003
PLoS One. 2013 Sep 19;8(9):e75021
24069377
BMC Neurol. 2015 May 13;15:79
25966681
J Immunol. 2006 Sep 15;177(6):3542-53
16951313
Neurology. 1983 Nov;33(11):1444-52
6685237
Brain. 2009 May;132(Pt 5):1175-89
19339255
PLoS One. 2010 Aug 05;5(8):e11986
20700489
J Neuroimmunol. 2011 Aug 15;237(1-2):73-9
21737148
J Neuroimmunol. 2007 Jul;187(1-2):179-86
17537523
Ann Neurol. 2004 Aug;56(2):303-6
15293286
Scand J Clin Lab Invest. 2002;62(4):293-9
12476928
PLoS One. 2015 Apr 10;10(4):e0119681
25860354
Acta Neurol Scand. 2013 Dec;128(6):e33-6
23763388
Neuropathol Appl Neurobiol. 2005 Jun;31(3):292-303
15885066
Acta Neurol Scand. 2014 Oct;130(4):268-75
24943672
Brain. 2003 Apr;126(Pt 4):770-82
12615637
Blood. 2004 Nov 15;104(10):3021-7
15284119
Scand J Clin Lab Invest. 2012 Feb;72(1):1-13
22060747
Anesth Analg. 2008 Nov;107(5):1726-34
18931239